Lycia Therapeutics: Staben holds 55,448 shares

Q: How many LYCA shares did Steven Staben report holding?

Steven Staben reported 55,448 shares of Lycia Therapeutics common stock held directly, in an entry dated October 22, 2026.

Q: What LYCA stock options does Steven Staben hold?

The reported positions cover 166,345 shares at a $1.63 exercise price, 155,255 at $2.44, 22,179 at $2.35, and 110,896 at $3.70. Their expiration dates are October 19, 2031; June 27, 2034; February 9, 2036; and August 10, 2036, respectively.

Q: What are Steven Staben’s LYCA option vesting schedules?

The option position covering 166,345 shares is fully vested. The 155,255-share award began vesting as to 1/48 on July 27, 2024; the 22,179-share award began on February 1, 2026; and the 110,896-share award began on September 6, 2026. For each of the latter three awards, an additional 1/48 vests monthly thereafter, subject to service on each vesting date.

Three option positions follow monthly vesting schedules conditioned on continued service, while one position is fully vested.

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Lycia Therapeutics, Inc. Chief Scientific Officer and 10% owner Steven Staben reported direct holdings of 55,448 common shares and four stock-option positions. The options cover 166,345 underlying shares at a $1.63 exercise price, expiring October 19, 2031; 155,255 at $2.44, expiring June 27, 2034; 22,179 at $2.35, expiring February 9, 2036; and 110,896 at $3.70, expiring August 10, 2036. One position is fully vested; the other three vest monthly, subject to service on each vesting date.

Insights

Analyzing...

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Staben Steven

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) ^F1	--	--	--
holding	Stock Option (Right to Buy) ^F2	--	--	--
holding	Stock Option (Right to Buy) ^F3	--	--	--
holding	Stock Option (Right to Buy) ^F4	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 454,675 contracts (Direct); Common Stock — 55,448 shares (Direct)

Footnotes (4)

F1. The options are fully vested.
F2. The options vested as to 1/48 of the total award on July 27, 2024, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F3. The options vested as to 1/48 of the total award on February 1, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F4. The options vested as to 1/48 of the total award on September 6, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Direct common shares: 55,448 shares Option underlying shares: 166,345 shares Option underlying shares: 155,255 shares +2 more

5 metrics

Direct common shares 55,448 shares Reported in an entry dated October 22, 2026

Option underlying shares 166,345 shares Exercise price: $1.63; expiration: October 19, 2031

Option underlying shares 155,255 shares Exercise price: $2.44; expiration: June 27, 2034

Option underlying shares 22,179 shares Exercise price: $2.35; expiration: February 9, 2036

Option underlying shares 110,896 shares Exercise price: $3.70; expiration: August 10, 2036

Key Terms

Stock Option (Right to Buy), fully vested, vest monthly

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

fully vested financial

"The options are fully vested."

vest monthly financial

"an additional 1/48 of the award will vest monthly thereafter"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LYCA shares did Steven Staben report holding?

Steven Staben reported 55,448 shares of Lycia Therapeutics common stock held directly, in an entry dated October 22, 2026.

What LYCA stock options does Steven Staben hold?

The reported positions cover 166,345 shares at a $1.63 exercise price, 155,255 at $2.44, 22,179 at $2.35, and 110,896 at $3.70. Their expiration dates are October 19, 2031; June 27, 2034; February 9, 2036; and August 10, 2036, respectively.

What are Steven Staben’s LYCA option vesting schedules?

The option position covering 166,345 shares is fully vested. The 155,255-share award began vesting as to 1/48 on July 27, 2024; the 22,179-share award began on February 1, 2026; and the 110,896-share award began on September 6, 2026. For each of the latter three awards, an additional 1/48 vests monthly thereafter, subject to service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/24/2026 - 08:14 PM EDT Accepted by SEC EDGAR 10/22/2026 - 07:15 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Staben Steven

(Last)

(First)

(Middle)

C/O LYCIA THERAPEUTICS, INC.

400 EAST JAMIE COURT, SUITE 200

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/22/2026

3. Issuer Name and Ticker or Trading Symbol
Lycia Therapeutics, Inc. [ LYCA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	55,448	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	10/19/2031	Common Stock	166,345	$1.63	D
Stock Option (Right to Buy)	⁽²⁾	06/27/2034	Common Stock	155,255	$2.44	D
Stock Option (Right to Buy)	⁽³⁾	02/09/2036	Common Stock	22,179	$2.35	D
Stock Option (Right to Buy)	⁽⁴⁾	08/10/2036	Common Stock	110,896	$3.7	D

Explanation of Responses:

1. The options are fully vested.

2. The options vested as to 1/48 of the total award on July 27, 2024, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

3. The options vested as to 1/48 of the total award on February 1, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

4. The options vested as to 1/48 of the total award on September 6, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Amy Bachrodt, Attorney-in-Fact	10/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR